Alagu Sankareswaran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alagu Sankareswaran has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Giriraj Ratan Chandak
CSIR-Centre for Cellular and Molecular Biology, Hyderabad, Telangana, India
4 shared publications Dimple Lavanuru
3 shared publications- Suraj S. Nongmaithem
Genomic Research on Complex Diseases Group (GRC-Group), CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB), Hyderabad, India
3 shared publications - Akila Prashant
Department of Biochemistry, JSS Medical College, JSS Academy of Higher Education & Research, Mysuru, India
2 shared publications - Chittaranjan Sakerlal Yajnik
Diabetes Unit, Kamalnayan Bajaj Diabetology Research Centre, King Edward Memorial Hospital and Research Centre, Pune, India
2 shared publications Mobeen Shaik
Genomic Research on Complex Diseases Group (GRC‐Group) CSIR‐Centre for Cellular and Molecular Biology (CSIR‐CCMB) Hyderabad India
2 shared publications
Latest Publications
- Open Access
- 26 February 2026
- Published by Elsevier in SSRN Electronic Journal
Performance of a Type 1 Diabetes Genetic Risk Score in a Multi-Centric Study from India and its Implications in Clinical Practice
Background: Genetic risk scores (GRS) for type 1 diabetes (T1D) have been developed primarily in European populations, limiting their generalisability across ancestries. Indians differ from Europeans in clinical characteristics of T1D and overall genetic architecture, yet systematic evaluation of T1D GRS performance in multi-regional Indian cohorts is lacking.Methods: The study included 597 T1D patients and 3347 non-diabetic controls from different regions in India. Genotyping, imputation, quality control analysis, and construction of the 67-SNPs T1D GRS were performed using standardised pipelines. Discriminative performance was assessed using Receiver Operative Curve-Area under Curve (ROC-AUC) analysis, and optimal thresholds were derived using Youden’s index. HLA-DQ diplotype frequencies were compared, and association analysis was conducted using multivariable logistic regression.Findings: T1D GRS showed consistent discriminative performance across Indian cohorts [ROC-AUC=0.84 (range=0·78-0·87)], supporting its comprehensive use for T1D classification in India. Notably, its performance was lower in islet cell autoantibody (IA) negative compared with IA positive T1D patients (ROC-AUC, 0·75 vs 0·85) and in adult-onset than in childhood-onset patients (0·74 vs 0·84). We observed a lower frequency of protective HLA-DQ diplotypes and a strong association of HLA-DQ81 containing diplotypes in childhood-onset T1D. Application of an India-specific T1D GRS score improved the sensitivity than the European cut-off.Interpretation: T1D GRS is a valuable unified diagnostic tool in Indians, but its performance varies by islet cell autoantibody status and age at onset, likely reflecting population-specific HLA architecture. European-derived T1D GRS thresholds under-classify the genetic risk, highlighting the importance of ancestry-aware optimisation in Indians.
- 26 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPerformance of a Type 1 Diabetes Genetic Risk Score in a Multi-Centric Study from India and its Implications in Clinical Practice
Background: Genetic risk scores (GRS) for type 1 diabetes (T1D) have been developed primarily in European populations, limiting their generalisability across ancestries. Indians differ from Europeans in clinical characteristics of T1D and overall genetic architecture, yet systematic evaluation of T1D GRS performance in multi-regional Indian cohorts is lacking.Methods: The study included 597 T1D patients and 3347 non-diabetic controls from different regions in India. Genotyping, imputation, quality control analysis, and construction of the 67-SNPs T1D GRS were performed using standardised pipelines. Discriminative performance was assessed using Receiver Operative Curve-Area under Curve (ROC-AUC) analysis, and optimal thresholds were derived using Youden’s index. HLA-DQ diplotype frequencies were compared, and association analysis was conducted using multivariable logistic regression.Findings: T1D GRS showed consistent discriminative performance across Indian cohorts [ROC-AUC=0.84 (range=0·78-0·87)], supporting its comprehensive use for T1D classification in India. Notably, its performance was lower in islet cell autoantibody (IA) negative compared with IA positive T1D patients (ROC-AUC, 0·75 vs 0·85) and in adult-onset than in childhood-onset patients (0·74 vs 0·84). We observed a lower frequency of protective HLA-DQ diplotypes and a strong association of HLA-DQ81 containing diplotypes in childhood-onset T1D. Application of an India-specific T1D GRS score improved the sensitivity than the European cut-off.Interpretation: T1D GRS is a valuable unified diagnostic tool in Indians, but its performance varies by islet cell autoantibody status and age at onset, likely reflecting population-specific HLA architecture. European-derived T1D GRS thresholds under-classify the genetic risk, highlighting the importance of ancestry-aware optimisation in Indians.
- Open Access
Performance of a Type 1 Diabetes Genetic Risk Score in a Multi-centric Study from India and its Implications in Clinical Practice
Summary: Background: Genetic risk scores (GRS) for type 1 diabetes (T1D) have been developed primarily in European populations, limiting their generalisability across ancestries. Indians differ from Europeans in clinical characteristics of T1D and overall genetic architecture, yet systematic evaluation of T1D GRS performance in multi-regional Indian cohorts is lacking. Methods: The study included 597 T1D patients and 3347 non-diabetic controls from different regions in India. Genotyping, imputation, quality control analysis, and construction of the 67-SNPs T1D GRS were performed using standardised pipelines. Discriminative performance was assessed using Receiver Operative Curve-Area under Curve (ROC-AUC) analysis, and optimal thresholds were derived using Youden’s index. HLA-DQ diplotype frequencies were compared, and association analysis was conducted using multivariable logistic regression. Findings: T1D GRS showed consistent discriminative performance across Indian cohorts [ROC-AUC=0.84 (range=0·78-0·87)], supporting its comprehensive use for T1D classification in India. Notably, its performance was lower in islet cell autoantibody (IA) negative compared with IA positive T1D patients (ROC-AUC, 0·75 vs 0·85) and in adult-onset than in childhood-onset patients (0·74 vs 0·84). We observed a lower frequency of protective HLA-DQ diplotypes and a strong association of HLA-DQ81 containing diplotypes in childhood-onset T1D. Application of an India-specific T1D GRS score improved the sensitivity than the European cut-off. Interpretation: T1D GRS is a valuable unified diagnostic tool in Indians, but its performance varies by islet cell autoantibody status and age at onset, likely reflecting population-specific HLA architecture. European-derived T1D GRS thresholds under-classify the genetic risk, highlighting the importance of ancestry-aware optimisation in Indians. Funding: CDRC grant CDRC202111026 and CSIR Intramural Grant P50. Research in context: Evidence before this study: Previous studies have shown that a 67-SNPs T1D genetic risk score (GRS) can distinguish T1D patients from non-diabetic controls and other forms of diabetes, but its performance varies across ancestries. Islet cell autoantibodies (IA) have important diagnostic value for classifying type 1 diabetes (T1D). However, their prevalence in India varies widely, with up to one-quarter of patients testing negative, limiting their clinical utility. Evidence supporting the use of the T1D GRS in India, combined with IA antibodies status is limited to a single cohort representing one linguistic group. The applicability of T1D GRS across multi-centric clinical settings has not been systematically evaluated. Added value of this study: This study validates the 67-SNPs T1D GRS across multiple Indian cohorts representing major linguistic groups, supporting its use as a unified diagnostic tool. Differences in T1DGRS performance between childhood-and adult-onset T1D are linked to enrichment of protective HLA-DQ diplotypes in adult-onset disease, providing genetic insight into disease heterogeneity. The study also demonstrates that European-derived GRS thresholds systematically under-classify genetic risk in Indians and the population-specific threshold is essential. Implications of all the available evidence: The European-derived T1D GRS can be applied across Indian clinical settings with consistent discriminative performance. However, its utility is influenced by islet cell autoantibody status and the age at onset of disease. Ancestry-aware threshold optimisation substantially improves diagnostic accuracy and is essential for equitable implementation of T1D GRS in Indians. Larger studies are needed to identify population-specific risk variants and further refine genetic tools for clinical diagnosis.
Open AccessPerformance of a Type 1 Diabetes Genetic Risk Score in a Multi-centric Study from India and its Implications in Clinical Practice
Summary: Background: Genetic risk scores (GRS) for type 1 diabetes (T1D) have been developed primarily in European populations, limiting their generalisability across ancestries. Indians differ from Europeans in clinical characteristics of T1D and overall genetic architecture, yet systematic evaluation of T1D GRS performance in multi-regional Indian cohorts is lacking. Methods: The study included 597 T1D patients and 3347 non-diabetic controls from different regions in India. Genotyping, imputation, quality control analysis, and construction of the 67-SNPs T1D GRS were performed using standardised pipelines. Discriminative performance was assessed using Receiver Operative Curve-Area under Curve (ROC-AUC) analysis, and optimal thresholds were derived using Youden’s index. HLA-DQ diplotype frequencies were compared, and association analysis was conducted using multivariable logistic regression. Findings: T1D GRS showed consistent discriminative performance across Indian cohorts [ROC-AUC=0.84 (range=0·78-0·87)], supporting its comprehensive use for T1D classification in India. Notably, its performance was lower in islet cell autoantibody (IA) negative compared with IA positive T1D patients (ROC-AUC, 0·75 vs 0·85) and in adult-onset than in childhood-onset patients (0·74 vs 0·84). We observed a lower frequency of protective HLA-DQ diplotypes and a strong association of HLA-DQ81 containing diplotypes in childhood-onset T1D. Application of an India-specific T1D GRS score improved the sensitivity than the European cut-off. Interpretation: T1D GRS is a valuable unified diagnostic tool in Indians, but its performance varies by islet cell autoantibody status and age at onset, likely reflecting population-specific HLA architecture. European-derived T1D GRS thresholds under-classify the genetic risk, highlighting the importance of ancestry-aware optimisation in Indians. Funding: CDRC grant CDRC202111026 and CSIR Intramural Grant P50. Research in context: Evidence before this study: Previous studies have shown that a 67-SNPs T1D genetic risk score (GRS) can distinguish T1D patients from non-diabetic controls and other forms of diabetes, but its performance varies across ancestries. Islet cell autoantibodies (IA) have important diagnostic value for classifying type 1 diabetes (T1D). However, their prevalence in India varies widely, with up to one-quarter of patients testing negative, limiting their clinical utility. Evidence supporting the use of the T1D GRS in India, combined with IA antibodies status is limited to a single cohort representing one linguistic group. The applicability of T1D GRS across multi-centric clinical settings has not been systematically evaluated. Added value of this study: This study validates the 67-SNPs T1D GRS across multiple Indian cohorts representing major linguistic groups, supporting its use as a unified diagnostic tool. Differences in T1DGRS performance between childhood-and adult-onset T1D are linked to enrichment of protective HLA-DQ diplotypes in adult-onset disease, providing genetic insight into disease heterogeneity. The study also demonstrates that European-derived GRS thresholds systematically under-classify genetic risk in Indians and the population-specific threshold is essential. Implications of all the available evidence: The European-derived T1D GRS can be applied across Indian clinical settings with consistent discriminative performance. However, its utility is influenced by islet cell autoantibody status and the age at onset of disease. Ancestry-aware threshold optimisation substantially improves diagnostic accuracy and is essential for equitable implementation of T1D GRS in Indians. Larger studies are needed to identify population-specific risk variants and further refine genetic tools for clinical diagnosis.
- 25 April 2025
- Published by Wiley in Diabetic Medicine
- Vol. 42 (8) , e70041
HLA haplotype diversity, islet autoantibody status and discriminative ability of type 1 diabetes genetic risk score in Indians
Aims: We have reported that a 9SNPs type 1 diabetes (T1D) Genetic Risk Score (GRS) developed from European data had a lower power in Indians to distinguish T1D from type 2 diabetes (T2D). We explore the performance of an improved (67SNPs) T1DGRS and also the potential reasons for lower discriminative ability to classify types of diabetes in Indians. Methods: We studied the discriminative ability of a 67SNPs European T1DGRS in 611 clinically diagnosed T1D and 1153 T2D patients, and 321 non‐diabetic controls, using receiver operating characteristic (ROC) area under the curve (AUC). We also compared the frequency and effect sizes of HLA risk haplotypes between Indians and Europeans. Results: The T1DGRS was discriminative of T1D from T2D and controls. However, the ability is lower in Indians than Europeans (AUC, Europeans 0.92, Indians all T1D 0.83, AA‐positive 0.86). The T1DGRS was higher in AA‐positive than in AA‐negative persons [13.01 (12.79–13.23) vs. 12.09 (11.64–12.56)], p < 0.0001. The association of common HLA‐DQA1 ~ HLA‐DQB1 haplotypes was broadly similar; however, important differences were noted in the frequency, direction and magnitude of effect for some haplotypes between Indians and Europeans. Conclusions: We confirm broad applicability of European 67SNPs T1DGRS to Indian T1D persons. However, differences in HLA allele frequencies, magnitude and directional differences reduced the predictive value. Our results stress the need to generate ancestry‐specific GRS, which we plan to do in the near future.
- 25 April 2025
- Published by Wiley in Diabetic Medicine
- Vol. 42 (8) , e70041
HLA haplotype diversity, islet autoantibody status and discriminative ability of type 1 diabetes genetic risk score in Indians
Aims: We have reported that a 9SNPs type 1 diabetes (T1D) Genetic Risk Score (GRS) developed from European data had a lower power in Indians to distinguish T1D from type 2 diabetes (T2D). We explore the performance of an improved (67SNPs) T1DGRS and also the potential reasons for lower discriminative ability to classify types of diabetes in Indians. Methods: We studied the discriminative ability of a 67SNPs European T1DGRS in 611 clinically diagnosed T1D and 1153 T2D patients, and 321 non‐diabetic controls, using receiver operating characteristic (ROC) area under the curve (AUC). We also compared the frequency and effect sizes of HLA risk haplotypes between Indians and Europeans. Results: The T1DGRS was discriminative of T1D from T2D and controls. However, the ability is lower in Indians than Europeans (AUC, Europeans 0.92, Indians all T1D 0.83, AA‐positive 0.86). The T1DGRS was higher in AA‐positive than in AA‐negative persons [13.01 (12.79–13.23) vs. 12.09 (11.64–12.56)], p < 0.0001. The association of common HLA‐DQA1 ~ HLA‐DQB1 haplotypes was broadly similar; however, important differences were noted in the frequency, direction and magnitude of effect for some haplotypes between Indians and Europeans. Conclusions: We confirm broad applicability of European 67SNPs T1DGRS to Indian T1D persons. However, differences in HLA allele frequencies, magnitude and directional differences reduced the predictive value. Our results stress the need to generate ancestry‐specific GRS, which we plan to do in the near future.
- Open Access
Type 1 Diabetes Genetic Risk Score classifies diabetes subtypes in Indians: Impact of HLA diversity on the lower discriminative ability
Objectives: Genetic Risk scores (GRS) classify diabetes types, type 1 (T1D) and type 2 (T2D) in Europeans but the power is limited in other ancestries. We explored the performance of T1DGRS and potential reasons for inferior discrimination ability in diabetes-type classification in Indians. Research Design and Methods: In a well-characterized Indian cohort comprising 645 clinically diagnosed T1D, 1153 T2D and 327 controls, we estimated the discriminative ability of T1DGRS (comprising 67 SNPs from Europeans) using receiver operating characteristics-area under the curve (ROC-AUC). We also compared the islet autoantibody status (AA), frequency and effect size of various HLA alleles/haplotypes between Indians and Europeans. Results: The T1DGRS was discriminative of T1D from T2D and controls but the ability is lower in Indians than Europeans (AUC=0.83 vs 0.92 respectively, p<0.0001). The T1DGRS was higher in AA-positive patients compared to AA-negative patients [13.01 (12.79-13.23) vs 12.09 (11.64-12.56)], p<0.0001) and showed greater discrimination in the AA-positive T1D (ROC-AUC 0.85). While association of common HLA-DQA1∼HLA-DQB1 haplotypes with T1D is replicated, important differences in the risk allele frequency, nature/direction and magnitude of association between Indians and Europeans were noted. Conclusions: A T1DGRS derived from Europeans is discriminative of T1D in Indians, highlighting similarity in heritability of T1D. Differences in allele frequency, effect size and directionality, especially in the HLA region are important contributors to inferior discrimination performance of T1DGRS in Indians. Further studies of diverse populations may improve its performance.
Open AccessType 1 Diabetes Genetic Risk Score classifies diabetes subtypes in Indians: Impact of HLA diversity on the lower discriminative ability
Objectives: Genetic Risk scores (GRS) classify diabetes types, type 1 (T1D) and type 2 (T2D) in Europeans but the power is limited in other ancestries. We explored the performance of T1DGRS and potential reasons for inferior discrimination ability in diabetes-type classification in Indians. Research Design and Methods: In a well-characterized Indian cohort comprising 645 clinically diagnosed T1D, 1153 T2D and 327 controls, we estimated the discriminative ability of T1DGRS (comprising 67 SNPs from Europeans) using receiver operating characteristics-area under the curve (ROC-AUC). We also compared the islet autoantibody status (AA), frequency and effect size of various HLA alleles/haplotypes between Indians and Europeans. Results: The T1DGRS was discriminative of T1D from T2D and controls but the ability is lower in Indians than Europeans (AUC=0.83 vs 0.92 respectively, p<0.0001). The T1DGRS was higher in AA-positive patients compared to AA-negative patients [13.01 (12.79-13.23) vs 12.09 (11.64-12.56)], p<0.0001) and showed greater discrimination in the AA-positive T1D (ROC-AUC 0.85). While association of common HLA-DQA1∼HLA-DQB1 haplotypes with T1D is replicated, important differences in the risk allele frequency, nature/direction and magnitude of association between Indians and Europeans were noted. Conclusions: A T1DGRS derived from Europeans is discriminative of T1D in Indians, highlighting similarity in heritability of T1D. Differences in allele frequency, effect size and directionality, especially in the HLA region are important contributors to inferior discrimination performance of T1DGRS in Indians. Further studies of diverse populations may improve its performance.
- Open Access
- 25 August 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-16
DNA methylation at the suppressor of cytokine signaling 3 (SOCS3) gene influences height in childhood
Human height is strongly influenced by genetics but the contribution of modifiable epigenetic factors is under-explored, particularly in low and middle-income countries (LMIC). We investigate links between blood DNA methylation and child height in four LMIC cohorts (n = 1927) and identify a robust association at three CpGs in the suppressor of cytokine signaling 3 (SOCS3) gene which replicates in a high-income country cohort (n = 879). SOCS3 methylation (SOCS3m)—height associations are independent of genetic effects. Mendelian randomization analysis confirms a causal effect of SOCS3m on height. In longitudinal analysis, SOCS3m explains a maximum 9.5% of height variance in mid-childhood while the variance explained by height polygenic risk score increases from birth to 21 years. Children’s SOCS3m is associated with prenatal maternal folate and socio-economic status. In-vitro characterization confirms a regulatory effect of SOCS3m on gene expression. Our findings suggest epigenetic modifications may play an important role in driving child height in LMIC.
- 25 August 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-16
Open AccessDNA methylation at the suppressor of cytokine signaling 3 (SOCS3) gene influences height in childhood
Human height is strongly influenced by genetics but the contribution of modifiable epigenetic factors is under-explored, particularly in low and middle-income countries (LMIC). We investigate links between blood DNA methylation and child height in four LMIC cohorts (n = 1927) and identify a robust association at three CpGs in the suppressor of cytokine signaling 3 (SOCS3) gene which replicates in a high-income country cohort (n = 879). SOCS3 methylation (SOCS3m)—height associations are independent of genetic effects. Mendelian randomization analysis confirms a causal effect of SOCS3m on height. In longitudinal analysis, SOCS3m explains a maximum 9.5% of height variance in mid-childhood while the variance explained by height polygenic risk score increases from birth to 21 years. Children’s SOCS3m is associated with prenatal maternal folate and socio-economic status. In-vitro characterization confirms a regulatory effect of SOCS3m on gene expression. Our findings suggest epigenetic modifications may play an important role in driving child height in LMIC.